Report Sections

See All Reports

  • HP:0011947: Respiratory tract infection
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0011947: Respiratory tract infection

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (80)


    Name (Synonyms) Correlation
    drug3621 VPM1002 Wiki 0.22
    drug3727 Women receiving extra remembering by healthcare Wiki 0.19
    drug2566 Placebo- 1.00 mg/kg Wiki 0.19
    Name (Synonyms) Correlation
    drug2001 Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Wiki 0.19
    drug1865 Lopinavir/ Ritonavir Wiki 0.19
    drug1551 Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets Wiki 0.19
    drug1103 Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) Wiki 0.19
    drug1314 Fidaxomicin Wiki 0.19
    drug2564 Placebo- 0.10 mg/kg Wiki 0.19
    drug701 CYNK-001 Wiki 0.19
    drug964 DAS181 COVID-19 Wiki 0.19
    drug3631 Vancomycin with Taper/Pulse Wiki 0.19
    drug1095 Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment Wiki 0.19
    drug420 BNT162a1 Wiki 0.19
    drug372 Azithromycin and hydroxychloroquine Wiki 0.19
    drug1097 Drug: GS-5734 - 2.00 mg/kg Wiki 0.19
    drug631 COVID-19 Breastfeeding Support Wiki 0.19
    drug1099 Drug: NA-831 Wiki 0.19
    drug2145 NaCl Solution Wiki 0.19
    drug3254 Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection Wiki 0.19
    drug1867 Lopinavir/ Ritonavir Placebo Wiki 0.19
    drug965 DAS181 OL Wiki 0.19
    drug3256 Standard therapy recommended by the Ministry of Health of the Russian Federation. Wiki 0.19
    drug1100 Drug: NA-831 - 0.10 mg/kg Wiki 0.19
    drug2553 Placebo on a 0- and 14-day schedule Wiki 0.19
    drug1372 GPs reports of potential patient safety incidents, non-COVID-19 related Wiki 0.19
    drug1885 Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Wiki 0.19
    drug1242 Exercise training Wiki 0.19
    drug2567 Placebo- 2.00 mg/kg Wiki 0.19
    drug1096 Drug: GS-5734 - 1.00 mg/kg Wiki 0.19
    drug424 BNT162c2 Wiki 0.19
    drug1101 Drug: NA-831 - 0.20 mg/kg Wiki 0.19
    drug2335 Only Standard Treatment Wiki 0.19
    drug3425 Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals Wiki 0.19
    drug2201 Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation Wiki 0.19
    drug3630 Vancomycin Wiki 0.19
    drug1162 Eicosapentaenoic acid gastro-resistant capsules Wiki 0.19
    drug1479 High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Wiki 0.19
    drug3253 Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation Wiki 0.19
    drug628 COVID-19 Androgen Sensitivity Test (CoVAST) Wiki 0.19
    drug2565 Placebo- 0.20 mg/kg Wiki 0.19
    drug2156 Naso pharyngeal swab Wiki 0.19
    drug1104 Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg) Wiki 0.19
    drug329 Atazanavir and Dexamethasone Wiki 0.19
    drug2515 Placebo 0.10 mg + 1.00 mg/kg Wiki 0.19
    drug679 COVSurf Drug Delivery System Wiki 0.19
    drug2758 Quick Defense Wiki 0.19
    drug3255 Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation Wiki 0.19
    drug2516 Placebo 0.20 mg + 2.00 mg/kg Wiki 0.19
    drug1157 Educational Program on Air Pollution as a Health Risk Reduction Strategy Wiki 0.19
    drug2122 NA-831 and Atazanavir Wiki 0.19
    drug2123 NA-831and Dexamethasone Wiki 0.19
    drug1499 Home-use Test and Follow-up Questionnaire Wiki 0.19
    drug1498 Home-based exercise Wiki 0.19
    drug1866 Lopinavir/ Ritonavir Oral Tablet Wiki 0.19
    drug1436 HCQ & AZ vs HCQ+SIR Wiki 0.19
    drug3677 Vitamin D 1000 IU Wiki 0.19
    drug1829 Levamisole and isoprinosine Wiki 0.19
    drug4155 trimethoprim/sulfamethoxazole Wiki 0.19
    drug1742 Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment Wiki 0.19
    drug1550 Hydroxychloroquine Sulfate Tablets Wiki 0.14
    drug2002 Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki 0.14
    drug1613 Icosapent ethyl Wiki 0.14
    drug1304 Favipiravir Placebo Wiki 0.14
    drug2554 Placebo on a 0- and 28-day schedule Wiki 0.14
    drug1886 Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki 0.14
    drug422 BNT162b2 Wiki 0.14
    drug1480 High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki 0.14
    drug68 ACE inhibitor Wiki 0.11
    drug421 BNT162b1 Wiki 0.11
    drug1296 Favipiravir Wiki 0.09
    drug3257 Standard treatment Wiki 0.08
    drug963 DAS181 Wiki 0.08
    drug2351 Oseltamivir Wiki 0.07
    drug229 Anakinra Wiki 0.07
    drug1030 Dexamethasone Wiki 0.06
    drug2505 Placebo Wiki 0.06
    drug3485 Tocilizumab Wiki 0.03
    drug3221 Standard of Care Wiki 0.03
    drug1520 Hydroxychloroquine Wiki 0.02

    Correlated MeSH Terms (27)


    Name (Synonyms) Correlation
    D012141 Respiratory Tract Infections NIH 0.93
    D030341 Nidovirales Infections NIH 0.27
    D012327 RNA Virus Infections NIH 0.24
    Name (Synonyms) Correlation
    D003141 Communicable Diseases NIH 0.19
    D003333 Coronaviridae Infections NIH 0.17
    D007239 Infection NIH 0.16
    D014777 Virus Diseases NIH 0.15
    D050197 Atherosclerosis NIH 0.14
    D058345 Asymptomatic Infections NIH 0.14
    D009410 Nerve Degeneration NIH 0.14
    D012140 Respiratory Tract Diseases NIH 0.12
    D018184 Paramyxoviridae Infections NIH 0.11
    D003139 Common Cold NIH 0.11
    D045169 Severe Acute Respiratory Syndrome NIH 0.09
    D007154 Immune System Diseases NIH 0.08
    D011665 Pulmonary Valve Insufficiency NIH 0.07
    D018352 Coronavirus Infections NIH 0.07
    D014808 Vitamin D Deficiency NIH 0.07
    D029424 Pulmonary Disease, Chronic Obstructive NIH 0.06
    D008173 Lung Diseases, Obstructive NIH 0.05
    D007251 Influenza, Human NIH 0.05
    D011014 Pneumonia NIH 0.04
    D008171 Lung Diseases, NIH 0.04
    D000860 Hypoxia NIH 0.04
    D002318 Cardiovascular Diseases NIH 0.04
    D011024 Pneumonia, Viral NIH 0.02
    D013577 Syndrome NIH 0.02

    Correlated HPO Terms (10)


    Name (Synonyms) Correlation
    HP:0002180 Neurodegeneration HPO 0.14
    HP:0002621 Atherosclerosis HPO 0.14
    HP:0100512 Low levels of vitamin D HPO 0.07
    Name (Synonyms) Correlation
    HP:0010444 Pulmonary insufficiency HPO 0.07
    HP:0006510 Chronic pulmonary obstruction HPO 0.06
    HP:0006536 Pulmonary obstruction HPO 0.06
    HP:0002088 Abnormal lung morphology HPO 0.04
    HP:0002090 Pneumonia HPO 0.04
    HP:0012418 Hypoxemia HPO 0.04
    HP:0001626 Abnormality of the cardiovascular system HPO 0.04

    Clinical Trials

    Navigate: Correlations   HPO

    There are 27 clinical trials


    1 SEA022 Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study.

    Currently, there is no treatment for children less than one year of age with influenza related lower respiratory tract infection that is either considered standard or registered in any country. This dismal scenario exists even though influenza related LRTI is a significant illness causing morbidity and mortality, especially in children less than 6 months of age. Avian influenza has been reported rarely in children less than one. There are no data in Vietnam and very few data in Thailand on the burden of influenza in children less than one. This young age group suffers high mortality. Oseltamivir may be beneficial in such children. This is basis of this trial.

    NCT01546935
    Conditions
    1. Influenza
    Interventions
    1. Drug: Oseltamivir
    MeSH:Infection Respiratory Tract Infections Influenza, Human
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: Viral clearance on Day 5 (human influenza) on a throat swab, assessed by RT PCR. Viral clearance on Day 10 (avian influenza) on a throat swab, assessed by RT PCR.

    Measure: Viral clearance

    Time: 5-10 days

    Description: • Cmax, Tmax, AUC, apparent volume of distribution, clearance, terminal elimination half-life

    Measure: Pharmacokinetics of Oseltamivir

    Time: Day 0 and Day 9

    Secondary Outcomes

    Description: Time to viral clearance on a throat swab, assessed by RT PCR. The time to no detectable influenza virus by culture for the throat swab. Change in viral load (log10 copies/mL) over time for all virological samples (lower limit of detection: 1000 copies/mL) Viral susceptibility of cultured influenza virus to antiviral drugs at baseline and post treatment, assessed by genotypical and phenotypical analyses

    Measure: Viral end points

    Time: 5-10 days

    Description: Time to fever clearance In hospital mortality and mortality by follow up Time to death Time to trans cutaneous O2 saturation of ≥ 95% on room air Clinical course: pneumothorax, encephalitis/encephalopathy Number of days in hospital Number of days ventilated

    Measure: Clinical Efficacy Endpoints

    Time: 5-10 days

    Description: Documented serious adverse events (SAEs) and relationships to oseltamivir AEs leading to drug withdrawal Grade 3 & 4 clinical and laboratory AEs that are probably or definitely related to oseltamivir Skin rashes of any grade Changes in haematological and biochemical parameters over time

    Measure: Safety Endpoints

    Time: 5-10 days
    2 Efficacy of Ingesting Gaia Herb's Quick Defense Product in Reducing Acute Respiratory Illness Symptomatology in Women: a 12-Week, Double Blind, Placebo-Controlled Randomized Trial

    The primary objective of this study is to evaluate the effectiveness of ingesting an alkylamide-rich echinacea root product (Quick Defense, Gaia Herbs) for 2 days immediately following each onset of acute respiratory illness (ARI) symptomatology during a 12-week period in the winter and early spring in women. Hypothesis: Subjects randomized to Quick Defense compared to placebo over a 12-week period will experience reduced ARI symptomatology, both acutely during each ARI episode and collectively over the entire 12-week study period.

    NCT02003651
    Conditions
    1. Acute Respiratory Infections
    Interventions
    1. Dietary Supplement: Quick Defense
    2. Dietary Supplement: Placebo
    MeSH:Respiratory Tract Infections
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: The Wisconsin Upper Respiratory Symptom Survey (WURSS-24) will be used to assess common cold illness severity and symptoms (see attached questionnaire). Subjects will fill in the one-page WURSS-24 at the end of each day during the 12-week monitoring period. This 12-week period will cover the winter and early spring period of 2014. From the responses recorded during the 84-day study, an ARI severity score will be calculated by summing the daily ARI global severity score (0=not sick, 1=very mild ARI to 7=severe). The ARI symptom score for the 84-day period will be calculated by summing all 10 symptom scores for each day's entry (0=do not have this symptom, 1=very mild to 7=severe). In similar fashion, the ARI function ability score for the 84-day period will be calculated by summing all 9 function scores for each day's entry (0=do not have this symptom, 1=very mild to 7=severe). Separate scores will be calculated comparing groups for each illness episode recorded by the subjects.

    Measure: Common cold symptoms

    Time: 12-weeks
    3 Assessment of Pharyngeal Carriage of Microorganisms Responsible for Transmissible Acute Respiratory Infections in HAJJ Pilgrims.

    The objective of this project is to study the prevalence of viruses and bacteria responsible for transmissible acute respiratory infections in the respiratory tract of pilgrims returning from the trip. The patients included, will be the consultant pilgrims to the traveler health center, and before leaving for Hajj. Based on the results obtained in previous studies, it is estimated that 200 pilgrims will be included each year, 600 in total (inclusion period of 3 years). Respiratory secretions are then collected by nasal swab and throat (swab) prior to departure for the hajj. In return, patients will be reconvened systematic consultation to record medical events potentially encountered during the trip, and it will again be performed the same nasal swabs and throat. It will then be performed on these samples' return from hajj "molecular detection (PCR and RT-PCR) of 35 viruses and bacteria respiratory tropism: influenza (3), RSV (2), metapneumovirus (1), Coronavirus (4), Parainfluenzavirus (4), enteroviruses (4), rhinovirus (1), adenovirus (6) bocavirus, polyomavirus (2), pneumococcus, Bordetella pertussis, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Coxiella burnetii. Samples "return of hajj" positive should be cultured for the isolation of the strain. For patients positive return, it will be done further research of these 35 viruses and bacteria on samples "start of hajj," the same method described above. In addition to this systematic consultation, and if symptoms return, the pilgrims will be seen in consultation for a diagnosis evaluation and therapeutic management. This study will shed light on the acquisition of microorganisms respiratory tropism during the stay and on the potential risks associated with the circulation of these pathogens after the trip.

    NCT02868541
    Conditions
    1. Acute Respiratory Infection
    Interventions
    1. Other: Naso pharyngeal swab
    MeSH:Infection Respiratory Tract Infections
    HPO:Respiratory tract infection

    Primary Outcomes

    Measure: The number of new viruses and/or bacteria identified and characterized by respiratory and pharyngeal carriage among pilgrims between the departure and the return of Hajj

    Time: up to 3 years
    4 Trial of Respiratory Infections in Children for Enhanced Diagnostics

    The overall aim of the TREND study is to improve the differential diagnosis of bacterial and viral etiology in children below 5 years of age with clinical community acquired pneumonia. Specific objectives: - To assess the diagnostic accuracy of MxA for viral CAP (sub-study I) - To study etiologies in children with CAP (sub-study II) - To evaluate sensitivity and specificity for MariPOC® Respi test versus PCR for detection of respiratory viruses (sub-study III) - To assess sensitivity and specificity for a novel RPA-based point-of-care test versus PCR for detection of respiratory viruses (sub-study IV) - To assess long-term complications in children with CAP (sub-study V The study takes place at Sachs' Children and Youth hospital in Stockholm.

    NCT03233516
    Conditions
    1. Community-acquired Pneumonia
    MeSH:Respiratory Tract Infections Pneumonia
    HPO:Pneumonia Respiratory tract infection

    Primary Outcomes

    Description: Clinically relevant difference in MxA-levels between cases with viral and bacterial clinical CAP

    Measure: MxA - cases with viral and bacterial clinical CAP

    Time: 2021

    Description: Clinically relevant difference in MxA-levels between cases with viral clinical CAP and controls

    Measure: Mxa viral clinical CAP and controls

    Time: 2021

    Description: Proportion of respiratory pathogens in cases and controls, using real time PCR

    Measure: PCR - respiratory pathogens in cases and controls

    Time: 2020

    Description: Sensitivity and specificity for different respiratory viruses with MariPOC® Respi as compared to real-time PCR

    Measure: Sensitivity and specificity - MariPOC

    Time: 2021

    Description: Sensitivity and specificity for different respiratory viruses with a novel PCR-based point-of-care test as compared to PCR

    Measure: Sensitivity and specificity a novel PCR-based point-of-care test

    Time: 2021

    Description: Difference in asthma prevalence between cases and controls and difference in number of hospital-requiring respiratory infections between cases and controls after 3, 7 and 10 years

    Measure: Difference asthma prevalence and number of hospital-requiring respiratory infections - cases and controls,

    Time: 2027

    Secondary Outcomes

    Description: Clinically relevant difference in MxA-levels comparing cases with viral clinical CAP with cases with atypical and mixed viral-bacterial clinical CAP as well as with controls with and without presence of respiratory viruses by PCR

    Measure: Specific assessment of MxA as a clinical biomarker

    Time: 2021

    Description: Clinically relevant differences in MxA-levels in cases with regard to specific respiratory agents

    Measure: Specific assessment of MxA as a clinical biomarker

    Time: 2021

    Description: Sensitivity and specificity for MxA in identifying viral clinical CAP

    Measure: Specific assessment of MxA as a clinical biomarker

    Time: 2021

    Description: Sensitivity and specificity for identifying viral and bacterial infection respectively for CRP, PCT and combination test of CRP, PCT and MxA

    Measure: Specific assessment of MxA as a clinical biomarker

    Time: 2021

    Description: Difference in CRP and PCT between children with viral, bacterial, atypical bacterial and mixed viral-bacterial infection

    Measure: Assessment of PCT and CRP as clinical biomarkers

    Time: 2021

    Description: Differences in symptom, antibiotic treatment, acute complications, radiologic exams admission rate and length of stay between cases with viral, bacterial, atypical bacterial and mixed viral-bacterial infection

    Measure: Descriptive statistics of study cohort with regard to etiologic agent

    Time: 2020

    Description: Differences in symptom, antibiotic treatment, acute complications, radiologic exams admission rate and length of stay between cases who tested positive for respiratory virus by MariPOC® Respi as compared to those with a negative test

    Measure: Evaluation of MariPOC® Respi in a clinical setting

    Time: 2022

    Description: Number of hospital-requiring respiratory infections in cases and controls

    Measure: Assessment of long-term outcomes of children with CAP

    Time: 2027

    Description: Difference in asthma prevalence between cases with viral and bacterial clinical CAP as compared to an estimate of the prevalence in the general population

    Measure: Assessment of long-term outcomes of children with CAP

    Time: 2027

    Description: Difference in proportion of hospital-requiring respiratory infections between cases with viral, bacterial, atypical and mixed viral-bacterial infection

    Measure: Assessment of long-term outcomes of children with CAP

    Time: 2027

    Description: Difference in MxA-levels between PCR+/MariPOC® Respi+ and PCR+/MariPOC® Respi- study subjects.

    Measure: Evaluation of MariPOC® Respi

    Time: 2022

    Description: Estimation of etiology of cases using two levels of certainty (definitive as well as probable definition).

    Measure: Etiology of cases in TREND study

    Time: 2020
    5 An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults & Adolescents With Non-Tuberculous Mycobacteria, Burkholderia Spp, Aspergillus Spp and Corona-like Viral (Sub-Study) Infections

    Non tuberculous mycobacteria (NTM), Burkholdria spp, Aspergillus in the lung are almost impossible to eradicate with conventional antibiotics. In addition COVID-19 has know current treatment. These patients have few options to treat their lung infection. Nitric oxide has broad bactericidal and virucidal properties. It has been shown that nitric oxide was safe to be inhaled for similar cystic fibrosis patients and reduced drug resistant bacteria in the lungs. Further, research indicates that clinical isolates of NTM, Burkholderia spp, Aspergillus spp and Corona-like viruses can be eradicated by 160ppm NO exposure in the laboratory petri dish. This is not the first time inhaled NO treatment has been used in patients with difficult lung infections. This study will provide more data to see if NO therapy can reduce the bacterial load in the lungs, help the patients breath better; and in the case of COVID-19 act as a anti-viral agent resulting in the reduction of incidence of oxygen therapy, mechanical assistance of BIPAP, CPAP, intubation and mechanical ventilation during the study period.

    NCT03331445
    Conditions
    1. Respiratory Tract Infections
    2. Corona Virus Infection
    Interventions
    1. Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: Measure the number of unanticipated adverse events over the duration of the study protocol

    Measure: Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects

    Time: 26 Days

    Secondary Outcomes

    Description: Measure the change in absolute FEV1.0 change from baseline during 160 ppm inhalation therapy

    Measure: Measure the effect of 160ppm inhaled nitric oxide delivery on lung spirometry in NTM subjects

    Time: Day 5,12,19 and 26

    Description: Measure the difference from baseline NTM species bacterial load (0 to +4) in sputum during 160ppm nitric oxide inhalation therapy

    Measure: Measure the antimicrobial effect of 160ppm inhaled nitric oxide on lung NTM bacterial load in the sputum

    Time: Day 19 and 26

    Description: Measure the difference from baseline CRISS (0-100) during 160ppm nitric oxide inhalation therapy (lower score represents higher quality of life)

    Measure: Measure the effect of 160ppm inhaled nitric oxide on Quality of Life (CRISS) Score

    Time: Day 19 and 26

    Other Outcomes

    Description: Measuring reduction in the incidence of mechanical assistance including oxygen therapy, BIPAP, CPAP, intubation and mechanical ventilation during the study period.

    Measure: Sub-Study Primary Endpoint(s): Efficacy to reduce respiratory interventions

    Time: Day 26

    Description: Measured by death from all causes

    Measure: Efficacy in reduction of mortality

    Time: Day 26

    Description: Assessed by time to negative conversion of COVID-19 RT-PCR from upper respiratory tract

    Measure: Antiviral effect

    Time: Day 26

    Description: Time to clinical recovery as measured by resolution of clinical signs

    Measure: Efficacy on clinical improvement

    Time: Day 26

    Description: Measured by change in the Modified Jackson Cold Score

    Measure: Efficacy on the respiratory symptoms

    Time: Day 26
    6 A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

    This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.

    NCT03808922
    Conditions
    1. Lower Respiratory Tract Infection
    2. Parainfluenza
    3. Immunocompromised
    4. COVID-19
    Interventions
    1. Drug: DAS181
    2. Drug: Placebo
    3. Drug: DAS181 COVID-19
    4. Drug: DAS181 OL
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Paramyxoviridae Infections
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: Removal of all oxygen support (with stable SpO2)

    Measure: Percent of subjects who Return to Room Air (RTRA) (main study)

    Time: by Day 28

    Measure: Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)

    Time: Day 14

    Secondary Outcomes

    Measure: All-cause mortality rate (main study)

    Time: at Day 28

    Measure: Percent of subjects who Return to Room Air (RTRA) (main study)

    Time: by Day 21

    Measure: Time (in days) to RTRA (main study)

    Time: Days 10, 14, 21, 28

    Measure: Percent of subjects who achieve clinical stability (main study)

    Time: by Day 28

    Measure: Percent of subjects discharged (without mortality and hospice) (main study)

    Time: by Days 14, 21, 28 and 35

    Measure: Time (in days) to first hospital discharge (without hospice) (main study)

    Time: through Day 35

    Measure: Total number of inpatient days (main study)

    Time: up to Day 35

    Measure: Baseline SAD-RV infection-related mortality rate (main study)

    Time: at Day 28

    Measure: Baseline SAD-RV infection-related mortality rate (main study)

    Time: at Day 35

    Measure: All-cause mortality rate (main study)

    Time: at Day 35

    Measure: Change in pulmonary function (FEV1% predicted) (main study)

    Time: Day 1, Day 7, Day 14, Day 28

    Measure: Time to improved COVID19 clinical status (Sub-study)

    Time: Day 5, Day 10, Day 21, Day 28

    Measure: Time to RTRA

    Time: Day 10, Day 14, Day 21, Day 28

    Measure: Time to Clinical stability

    Time: Day 14, Day 21, Day 28

    Measure: Time to SARS-CoV-2 RNA in the respiratory specimens being undetectable

    Time: Day 5, Day 10, Day 14, Day 21, Day 28

    Measure: Time to Clinical deterioration

    Time: Day 5, Day 10, Day 14, Day 21, Day 28

    Measure: Time to Discharge from hospital (without readmission before Day 28).

    Time: Day 14, Day 21, Day 28

    Measure: Time to Death (all causes)

    Time: Day 14, Day 21, Day 28
    7 Effect of Counseling Between Pregnant Women During Corona Infection

    Corona virus is known as covid 19 And is transmitted through droplet infection

    NCT04317365
    Conditions
    1. Respiratory Tract Infections
    Interventions
    1. Other: Women receiving extra remembering by healthcare
    MeSH:Infection Respiratory Tract Infections
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: The number of pregnant women who have awareness about the disease

    Measure: The number of pregnant women who know the exact symptoms of the disease

    Time: Within one month
    8 Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals

    Operational project to compare clinician collected nasopharyngeal (NP) samples to patient-obtained tongue, nasal and mid-turbinate (MT) samples in the detection of SARS-CoV-2 in an outpatient clinic setting

    NCT04321369
    Conditions
    1. Infections, Respiratory
    2. Fever
    3. Cough
    Interventions
    1. Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals
    MeSH:Respiratory Tract Infections
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: compare clinician collected nasopharyngeal (NP) samples to patient-obtained tongue, nasal and mid-turbinate (MT) samples in the detection of SARS-CoV-2 in an outpatient clinic setting

    Measure: Accuracy of patient administered tests

    Time: 2 weeks
    9 The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective? An Analysis Using UK Based Electronic Health Records of 5.6 Million Individuals.

    The study use UK based linked electronic health records from the Clinical Research Datalink (CALIBER) of 5.6 million individuals to conduct a matched case-control study to investigate the incidence of influenza in individuals prescribed ACEI compared to those not prescribed ACEI.

    NCT04322786
    Conditions
    1. Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom
    Interventions
    1. Drug: ACE inhibitor
    MeSH:Respiratory Tract Infections
    HPO:Respiratory tract infection

    Primary Outcomes

    Measure: Incidence of influenza

    Time: Jan 1st 1998 - May 31st 2016
    10 Audio Data Collection for Identification and Classification of Coughing

    An open access study that will define and collect digital measures of coughing in multiple populations and public spaces using various means of audio data collection.

    NCT04326309
    Conditions
    1. COVID-19
    2. Coronavirus Infections
    3. Hay Fever
    4. Asthma
    5. Chronic Obstructive Pulmonary Disease
    6. Influenza
    7. Common Cold
    8. Respiratory Tract Infections
    9. Healthy
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome Common Cold Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive
    HPO:Chronic pulmonary obstruction Pulmonary obstruction Respiratory tract infection

    Primary Outcomes

    Description: Size of collected audio dataset measured as number of collected cough sounds, targeting ≥10,000 identified coughs.

    Measure: Dataset size

    Time: 14 days

    Secondary Outcomes

    Description: Identification of cough sounds by the existing mathematical model with ≥ 99% specificity and ≥ 60% sensitivity

    Measure: Cough sound identification

    Time: 14 days

    Description: Increase in the sensitivity of the mathematical model to cough sounds to ≥ 70% while retaining the specificity of ≥ 99%

    Measure: Improvement of the existing model

    Time: 14 days

    Description: Determination of the level of acceptance and satisfaction of the solution by patients by means of a Standard Usability Questionnaire to provide feedback. The score ranges from 10 to 50, higher score indicating a better usability.

    Measure: Evaluate the usability of the application

    Time: 14 days
    11 Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease

    ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19. Patients, treating clinicians, and study personnel will all be blinded to study group assignment.

    NCT04332991
    Conditions
    1. Coronavirus
    2. Acute Respiratory Infection
    3. SARS-CoV Infection
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: We will determine the COVID Ordinal Scale for all patients on study day 15 COVID Ordinal Scale defined as: Death Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation) Hospitalized on non-invasive ventilation or high flow nasal cannula Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with limitation in activity (continued symptoms) Not hospitalized without limitation in activity (no symptoms)

    Measure: COVID Ordinal Outcomes Scale on Day 15

    Time: assessed on study day 15

    Secondary Outcomes

    Description: Vital status of the patient on day 15 will be determined using any of the following methods: medical record review, phone calls to patient or proxy

    Measure: all-location, all-cause mortality assessed on day 15

    Time: assessed on study day 15

    Description: Vital status of the patient at day 28 will be determined using any of the following methods: medical record review, phone calls to patient or proxy

    Measure: all-location, all-cause mortality assessed on day 29

    Time: assessed on study day 29

    Description: We will determine the COVID Ordinal Scale for all patients on study day 3

    Measure: COVID Ordinal Outcomes Scale on Study Day 3

    Time: assessed on study day 3

    Description: We will determine the COVID Ordinal Scale on study day 8

    Measure: COVID Ordinal Outcomes Scale on Study Day 8

    Time: assessed on study day 8

    Description: We will determine the COVID Ordinal Scale on study day 29

    Measure: COVID Ordinal Outcomes Scale on Study Day 29

    Time: assessed on study day 29

    Description: We will determine the number of patients who are either dead or on ECMO ( extracorporeal membrane oxygenation) between enrollment and day 28

    Measure: Number of patients dead or with receipt of ECMO between enrollment and Day 28

    Time: Enrollment to Day 28

    Description: The number of calendar days between randomization and 28 days later that the patient is alive and without the use of oxygen therapy. Patients who die prior to day 28 are assigned zero oxygen free days.

    Measure: Oxygen-free days through Day 28

    Time: 28 days after randomization

    Description: Ventilator-free days is defined to be 28 days minus the duration of mechanical ventilation through day 28. Participants who do not survive to day 28 are assigned zero ventilator-free days.

    Measure: Ventilator-free days through Day 28

    Time: 28 days after randomization

    Description: The number of calendar days between randomization and 28 days later that the patient is alive and without the use of vasopressor therapy. Patients who die prior to day 28 are assigned zero vasopressor free days.

    Measure: Vasopressor-free days through Day 28

    Time: 28 days after randomization

    Description: The number of days spent out of the ICU to day 28.

    Measure: ICU-free days to Day 28

    Time: 28 days after randomization

    Description: Defined as 28 days minus the number of days from randomization to discharge home.If a patient has not been discharged home prior to day 28 or dies prior to day 28, hospital free days will be zero.

    Measure: Hospital-free days to Day 28

    Time: 28 days after randomization

    Other Outcomes

    Description: We will determine the number of patients that experience seizure between randomization and day 28

    Measure: Number of patients with seizures to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience ventricular arrhythmia between randomization and day 28

    Measure: Number of patients with atrial or ventricular arrhythmia to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience cardiac arrest between randomization and day 28

    Measure: Number of patients with cardiac arrest to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience elevation in aspartate aminotransferase or alanine aminotransferase to twice the local upper limit of normal between randomization and day 28

    Measure: Number of patients with elevation in aspartate aminotransferase or alanine aminotransferase to twice the local upper limit of normal to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience acute pancreatitis between randomization and day 28

    Measure: Number of patients with acute pancreatitis arrest to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience acute kidney injury between randomization and day 28

    Measure: Number of patients with acute kidney injury to day28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience renal replacement therapy between randomization and day 28

    Measure: Number of patients with receipt of renal replacement therapy to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience symptomatic hypoglycemia between randomization and day 28

    Measure: Number of patients with symptomatic hypoglycemia to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience neutropenia, lymphopenia, anemia, or thrombocytopenia between randomization and day 28

    Measure: Number of patients with neutropenia, lymphopenia, anemia, or thrombocytopenia to day 28

    Time: 28 days after randomization

    Description: We will determine the number of patients that experience severe dermatologic reaction between randomization and day 28

    Measure: Number of patients with severe dermatologic reaction to day 28

    Time: 28 days after randomization

    Description: Time to recovery, defined as time to reaching level 5, 6, or 7 on the COVID Outcomes Scale, which is the time to the earlier of final liberation from supplemental oxygen or hospital discharge

    Measure: Time to recovery, defined as time to reaching level 5, 6, or 7 on the COVID Outcomes Scale, which is the time to the earlier of final liberation from supplemental oxygen or hospital discharge

    Time: 28 days after randomization
    12 An Open Randomized Study of the Effectiveness of the Drug Dalargin for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19)

    The purpose of the study is to evaluate an effectiveness of the drug Dalargin for the prevention and treatment of severe pulmonary complications symptoms associated with severe and critical coronavirus infection cases (SARS COVID19, expanded as Severe acute respiratory syndrome Cоrona Virus Disease 2019 ). Test drug that will be administered to patients are: - Dalargin, solution for inhalation administration, - Dalargin, solution for intravenous and intramuscular administration.

    NCT04346693
    Conditions
    1. Acute Respiratory Tract Infection
    2. Acute Respiratory Insufficiency
    3. Pneumonia
    4. Septic Shock
    5. Hypoxemia
    Interventions
    1. Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.
    2. Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection
    3. Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation
    4. Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation
    MeSH:Infection Respiratory Tract Infections Pneumonia Respiratory Insufficiency Pulmonary Valve Insufficiency Hypoxia
    HPO:Hypoxemia Pneumonia Pulmonary insufficiency Respiratory tract infection

    Primary Outcomes

    Description: Estimated by Polymerase chain reaction (PCR)

    Measure: The change of viral load in patients with SARS-COVID-19.

    Time: Upon patient inclusion in the study, after 96 hours and on the 10day;

    Description: Assessed through the entire patient participation in the study

    Measure: The frequency of development of Acute Respiratory Distress Syndrome (ADRS)

    Time: up to 10 days

    Description: The number of days a patient is hospitalized

    Measure: Duration of hospitalization

    Time: up to 10 days

    Description: Early mortality from all causes will be estimated

    Measure: The frequency of early mortality

    Time: up to 30 days

    Description: Late mortality from all causes will be estimated

    Measure: The frequency of late mortality

    Time: up to 90 days

    Description: Clinical status at the time of completion of participation in the study will be estimated based upon the following criteria: Death; Hospitalization is extended, on invasive mechanical ventilation of the lungs with extracorporeal membrane oxygenation; Hospitalization extended, on non-invasive ventilation; Hospitalization is extended, needs additional oxygen; Hospitalization is extended, additional oxygen is not required; Discharged.

    Measure: Clinical status at the time of completion of participation in the study

    Time: an average of 10 days
    13 suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial

    In the SAVE study patients with lower respiratory tract infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at high risk for progression to serious respiratory failure will be detected using the suPAR biomarker. They will begin early treatment with anakinra in the effort to prevent progression in serious respiratory failure. Also due to the potential co-existing immunodysfunction in the context of SARS-CoV-2 infection patients will also receive trimethoprim/sulfamethoxazole as part of chemoprophylaxis.

    NCT04357366
    Conditions
    1. COVID-19
    2. Virus Dis
    3. Virus Diseases
    4. Corona Virus Infection
    5. Lower Respiratory Tract Infection Viral
    Interventions
    1. Drug: Anakinra
    2. Drug: trimethoprim/sulfamethoxazole
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Virus Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Respiratory Insufficiency
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: The primary study endpoint is the ratio of patients who will not develop serious respiratory failure SRF until day 14. Patients dying before study visit of day 14 are considered non-achieving the primary endpoint.

    Measure: The ratio of patients who will not develop serious respiratory failure (SRF)

    Time: Visit study day 14

    Secondary Outcomes

    Description: Evaluation of clinical data (pO2/FiO2 and need of mechanical ventilation) between baseline and study visit day 14 will be compared with historical comparators from Hellenic Sepsis Study Group Database

    Measure: Comparison of the rate of patients who will not develop serious respiratory failure (SRF) until day 14 with historical comparators from Hellenic Sepsis Study Group Database

    Time: Visit study day 14

    Description: Change of scoring for respiratory symptoms (evaluation of cough, chest pain, shortness of breath and sputum) in enrolled subjects between days 1 and 7

    Measure: Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 7

    Time: Visit study day 1, visit study day 7

    Description: Change of scoring for respiratory symptoms (evaluation of cough, chest pain, shortness of breath and sputum) in enrolled subjects between days 1 and 14

    Measure: Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 14

    Time: Visit study day 1, visit study day 14

    Description: Change of Sequential organ failure assessment (SOFA) score of enrolled subjects between days 1 and 7 (Sequential organ failure assessment range 0-24, high score associated with worst outcome)

    Measure: Change of SOFA score in enrolled subjects between days 1 and 7

    Time: Visit study day 1, visit study day 7

    Description: Change of Sequential organ failure assessment (SOFA) score of enrolled subjects between days 1 and 14 (Sequential organ failure assessment range 0-24, high score associated with worst outcome)

    Measure: Change of Sequential organ failure assessment (SOFA) score in enrolled subjects between days 1 and 14

    Time: Visit study day 1, visit study day 14

    Description: Change of cytokine stimulation from peripheral blood mononuclear cells of enrolled subjects will be compared between days 1 and 7

    Measure: Change of cytokine production between days 1 and 7

    Time: Visit study day 1, visit study day 7

    Description: Change of plasma inflammatory mediators measured levels will be compared between days 1 and 7

    Measure: Change of plasma inflammatory mediators levels between days 1 and 7

    Time: Visit study day 1, visit study day 7
    14 A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19

    Lung surfactant is present in the lungs. It covers the alveolar surface where it reduces the work of breathing and prevents the lungs from collapsing. In some respiratory diseases and in patients that require ventilation this substance does not function normally. This study will introduce surfactant to the patients lungs via the COVSurf Drug Delivery System

    NCT04362059
    Conditions
    1. Respiratory Infections
    Interventions
    1. Device: COVSurf Drug Delivery System
    2. Other: Standard of Care
    MeSH:Respiratory Tract Infections
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: To assess the improvement in oxygenation as determined by the PaO2/FiO2 ratio after treatment with study treatment

    Measure: Oxygenation Improvement

    Time: 3 months

    Description: To assess the improvement in pulmonary ventilation as determined by the Ventilation Index (VI), where VI = [RR x (PIP - PEEP) × PaCO2]/1000 after study treatment.

    Measure: Pulmonary ventilation Improvement

    Time: 3 months

    Secondary Outcomes

    Description: To assess safety as judged by the frequency and severity of adverse events and severe adverse events (SAEs).

    Measure: Safety Assessment of Frequency and Severity of Adverse Events

    Time: 3 months
    15 A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19

    This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

    NCT04365101
    Conditions
    1. Coronavirus
    2. Coronavirus Infection
    3. Severe Acute Respiratory Syndrome Coronavirus 2
    4. Pneumonia
    5. Pneumonia, Viral
    6. Lung Diseases
    7. Respiratory Tract Disease
    8. Respiratory Tract Infections
    9. Coronaviridae Infections
    10. Nidovirales Infections
    11. RNA Virus Infections
    12. Virus Disease
    13. Immunologic Disease
    14. ARDS
    15. Immunologic Factors
    16. Physiological Effects of Drugs
    17. Antiviral Agents
    18. Anti-infective Agents
    19. Analgesic
    20. Analgesics
    21. Antimetabolites, Antineoplastic
    Interventions
    1. Biological: CYNK-001
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Virus Diseases Coronavirus Infections Severe Acute Respiratory Syndrome RNA Virus Infections Pneumonia, Viral Coronaviridae Infections Nidovirales Infections Pneumonia Lung Diseases Respiratory Tract Diseases Immune System Diseases
    HPO:Abnormal lung morphology Pneumonia Respiratory tract infection

    Primary Outcomes

    Description: Number and severity of adverse events

    Measure: Phase 1: Frequency and Severity of Adverse Events (AE)

    Time: Up to 6 months

    Description: Proportion of subjects with "negative" measurement of COVID-19 by rRT-PCR

    Measure: Phase 1: Rate of clearance of SARS-CoV-2

    Time: Up to 6 months

    Description: Proportion of subjects who improved clinical symptoms related to lower respiratory tract infection, as measured by National Early Warning Score 2 (NEWS2) score.

    Measure: Phase 1: Rate of clinical improvement

    Time: Up to 6 months

    Description: Time from the date of randomization to the clearance of SARS-CoV-2 by rRT-PCR. Negative results will need to be confirmed by a second negative result in the same sample type at least 24 hours after the first negative result.

    Measure: Phase 2: Time to Clearance of SARS-CoV-2

    Time: Up to 28 days

    Description: Time from the date of randomization to the first date of improved clinical symptoms related to lower respiratory tract infection. Improvement as measured by National Early Warning Score 2 (NEWS2) Score.

    Measure: Phase 2: Time to Clinical Improvement by NEWS2 Score

    Time: Up to 28 days

    Secondary Outcomes

    Description: Proportion of subjects with "negative" measurement of COVID-19 by rRT-PCR

    Measure: Rate of Clearance of SARS-CoV-2

    Time: Up to 6 months

    Description: Number and severity of adverse events

    Measure: Phase 2: Frequency and Severity of Adverse Events (AE)

    Time: up to 6 months

    Description: Time to medical discharge as an assessment of overall clinical benefit

    Measure: Overall Clinical Benefit by time to medical discharge

    Time: up to 6 months

    Description: Hospital utilization will be measured as an assessment of overall clinical benefit

    Measure: Overall Clinical Benefit by hospital utilization

    Time: up to 6 months

    Description: Mortality rate will be measured as an assessment of overall clinical benefit

    Measure: Overall Clinical Benefit by measuring mortality rate

    Time: up to 6 months

    Description: Assess the impact of CYNK-001 on changes in sequential organ failure assessment (SOFA) score.

    Measure: Impact of CYNK-001 on sequential organ failure assessment (SOFA) score

    Time: Up to 28 days

    Description: Time from randomization to the date of disappearance of virus from lower respiratory tract infection (LRTI) specimen where it has previously been found (induced sputum, endotracheal aspirate).

    Measure: Time to Pulmonary Clearance

    Time: Up to 28 days

    Description: For ventilatory support subjects, the days with supplemental oxygen-free.

    Measure: Supplemental oxygen-free days

    Time: Up to 28 days

    Description: Proportion of subjects who need invasive or non-invasive ventilation

    Measure: Proportion of subjects requiring ventilation

    Time: Up to 28 days
    16 Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2

    The SARS-CoV2 virus causes severe or even fatal disease in a fraction of infected people. The clinical severity is based on a complicated pneumopathy with acute respiratory distress syndrome that can lead to multi-visceral failure. The underlying mechanism is a cytokinergic storm, an emerging facet of immunological dysregulation. This clinical trial is aimed to understand the mechanisms of this immunological dysregulation in order to identify therapeutic levers. The main objective is to understand the relationships between clinical severity, death or morbidity of resuscitation management, and immune status (i.e., immune pathways activated or not). Immune status will be investigated at many levels of organization (i.e., circulating leukocytes, cytokines and chemokines, transcripts). The secondary objectives are : - to understand what is responsible for clinical severity, viral load, or immune activation; - to highlight the consequences of immunological dysregulation on associated risks (i.e., immunosuppression leading to the emergence of infectious comorbidities) as well as the functioning of neurotransmission through metabolic pathway diversions. The impact of dysimmunity on these biological pathways will be assessed with a metabolomic analysis; - to understand the mechanisms of vulnerability related to the field. Moreover, while co-morbidities are likely to be a risk factor for severe disease progression, there are many situations in which they do not occur. Stress, with its neurovegetative and endocrinological dimensions, modulates the immune response. It is essential to know whether the stress response plays a role in immunological dysregulation. This analysis is a prerequisite for understanding the conditions of treatment with glucocorticoids. Angiotensin converting enzyme type 2 (ACE2) also plays a likely role in host viral infection. It is also thought to play an important role in the emergence of severe syndromes by affecting the quality of vascular response.

    NCT04365166
    Conditions
    1. Respiratory Tract Infections
    2. Respiratory Tract Disease
    MeSH:Respiratory Tract Infections Respiratory Tract Diseases
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: Mortality

    Measure: Mortality

    Time: 90 days following the enrollment

    Description: Th1/Th2/Th17/Treg balance, Type I Interferons and inflammation

    Measure: Immune response - Plasma cytokine profile

    Time: Through study completion (90 days following the enrollment)

    Description: T cells (CD3, CD4, CD8, PD1, FAS, CD45RO, CTLA4+, CXCR5, CXCR3, CCR6, CD69, CD95, HLA-DR) and B cells (CD3, CD19, CD27, IgD, CD69) with cell subtypes and memory/naive compartments (CD27, CD38, IgD, IgG1, IgG2, IgG3, CD20, CD24), NK cells (CD14, CD16, CD56, HLA-DR), monocytes (CD14, CD45, HLA-DR, PDL-1)

    Measure: Immune response - Phenotype of circulating cells

    Time: Through study completion (90 days following the enrollment)

    Secondary Outcomes

    Description: Number of days in intensive care unit

    Measure: Severity criteria - Duration of stay in intensive care unit

    Time: 90 days following the enrollment

    Description: Number of days of hospitalization

    Measure: Severity criteria - Duration of hospitalization stay

    Time: 90 days following the enrollment

    Description: Number of days out of hospital

    Measure: Severity criteria - Duration of period out of hospital

    Time: 90 days following the enrollment

    Description: Number of days without mechanical ventilation (invasive/non-invasive)

    Measure: Severity criteria - Duration without mechanical ventilation

    Time: 90 days following the enrollment

    Description: Number of days not being ventilated

    Measure: Severity criteria - Duration without ventilation

    Time: 90 days following the enrollment

    Description: Number of days not being intubated

    Measure: Severity criteria - Duration without intubation

    Time: 90 days following the enrollment

    Description: Number of transfusions

    Measure: Severity criteria - Number of transfusions

    Time: 90 days following the enrollment

    Description: Number of days without cathecholamines

    Measure: Severity criteria - Duration of the period without cathecholamines

    Time: 90 days following the enrollment

    Description: Number of days without dialysis

    Measure: Severity criteria - Duration of the period without dialysis

    Time: 90 days following the enrollment

    Description: Sepsis-related Organ Failure Assessment (SOFA) Score

    Measure: Severity criteria - SOFA

    Time: Through study completion (90 days following the enrollment)

    Description: Lung Injury Score (LIS)

    Measure: Severity criteria - LIS

    Time: Through study completion (90 days following the enrollment)

    Description: SARS-Cov2 viral load will be measured in blood and in broncho-tracheal secretions

    Measure: SARS-Cov2 viral load

    Time: Through study completion (90 days following the enrollment)

    Description: Co-infections and acquired infections (bacterial or fungal) in intensive care unit, in particular based on an all-site positive PCR for EBV and/or CMV and/or HSV

    Measure: Emergence of concomitant infections

    Time: 90 days following the enrollment

    Description: T cells (CD3, CD4, CD8, PD1, FAS, CD45RO, CTLA4+, CXCR5, CXCR3, CCR6, CD69, CD95, HLA-DR) and B cells (CD3, CD19, CD27, IgD, CD69) with cell subtypes and memory/naive compartments (CD27, CD38, IgD, IgG1, IgG2, IgG3, CD20, CD24), NK cells (CD14, CD16, CD56, HLA-DR), monocytes (CD14, CD45, HLA-DR, PDL-1)

    Measure: Emergence of concomitant infections - Phenotype of circulating cells

    Time: Through study completion (90 days following the enrollment)

    Description: Heart rate variability

    Measure: Stress physiological profile - Sympathetic tone

    Time: Through study completion (90 days following the enrollment)

    Description: Core temperature

    Measure: Stress physiological profile - Temperature

    Time: Through study completion (90 days following the enrollment)

    Description: Quantity of glucocorticoids in the urine during 24 hours and at night

    Measure: Stress physiological profile - Glucocorticoids

    Time: Through study completion (90 days following the enrollment)

    Description: ACE Polymorphism

    Measure: Angiotensin converting enzyme type II (ACE2) polymorphism - ACE

    Time: At enrollment

    Description: Protein expression of ACE2 vs. ACE1 and angiotensin II chain proteins

    Measure: Angiotensin converting enzyme type II (ACE2) polymorphism - ACE2/ACE1

    Time: At enrollment

    Description: Diabete diagnosis

    Measure: Comorbidities - diabetes

    Time: At enrollment

    Description: Heart disease diagnosis

    Measure: Comorbidities - Heart disease

    Time: At enrollment

    Description: Organ failure diagnosis

    Measure: Comorbidities - organ failure

    Time: At enrollment

    Description: GABA level in blood and urine

    Measure: Plasma concentrations of several metabolic pathways - GABA

    Time: Through study completion (90 days following the enrollment)

    Description: Glucocorticoid level in blood and urine

    Measure: Plasma concentrations of several metabolic pathways - Glucocorticoid

    Time: Through study completion (90 days following the enrollment)

    Description: Tryptophan in blood and urine

    Measure: Plasma concentrations of several metabolic pathways - Tryptophan

    Time: Through study completion (90 days following the enrollment)

    Description: Serotonin level in blood and urine

    Measure: Plasma concentrations of several metabolic pathways - Serotonin

    Time: Through study completion (90 days following the enrollment)

    Description: Dopamin level in blood and urine

    Measure: Plasma concentrations of several metabolic pathways - Dopamin

    Time: Through study completion (90 days following the enrollment)

    Description: Catecholamines level in blood and urine

    Measure: Plasma concentrations of several metabolic pathways - Cathecholamines

    Time: Through study completion (90 days following the enrollment)

    Description: Arachidonic acid derivatives level in blood and urine

    Measure: Plasma concentrations of several metabolic pathways - Arachidonic acid derivatives

    Time: Through study completion (90 days following the enrollment)

    Description: Endocannabinoids level in blood and urine

    Measure: Plasma concentrations of several metabolic pathways - Endocannabinoids

    Time: Through study completion (90 days following the enrollment)
    17 A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy Adults

    The trial has two parts: Part A is for dose ranging with dose escalation and de-escalation plus the evaluation of interim dose levels. It also includes dose ranging in older subjects. Part B is dedicated to recruit expansion cohorts with dose levels which are selected from data generated in Part A. The vaccines BNT162a1, BNT162b1, BNT162b2, and BNT162c2 will be administered using a Prime/Boost (P/B) regimen. The vaccine BNT162c2 will also be administered using a Single dose (SD) regimen.

    NCT04380701
    Conditions
    1. Infections, Respiratory
    2. Virus Diseases
    3. Infection Viral
    4. Vaccine Adverse Reaction
    5. RNA Virus Infections
    Interventions
    1. Biological: BNT162a1
    2. Biological: BNT162b1
    3. Biological: BNT162b2
    4. Biological: BNT162c2
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Virus Diseases RNA Virus Infections
    HPO:Respiratory tract infection

    Primary Outcomes

    Measure: Solicited local reactions at the injection site (pain, tenderness, erythema/redness, induration/swelling) recorded up to 7±1 days after each immunization.

    Time: up to 7 days following each dose administration

    Measure: Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7±1 days after each immunization.

    Time: up to 7 days following each dose administration

    Description: For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B): occurring up to 21±2 days after the prime immunization.

    Measure: The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE):

    Time: 21 days following dose administration

    Description: For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B): occurring up to 28±4 days after the boost immunization. For BNT162c2 (SD): The proportion of subjects with at least 1 unsolicited TEAE occurring up to 28±4 days after the immunization.

    Measure: The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE):

    Time: 28 days following dose administration

    Secondary Outcomes

    Description: Functional antibody responses at 7±1 days and 21±2 days after primary immunization and at 21±2 days, 28±4 days, 63±5 days, and 162±7 days after the boost immunization.

    Measure: For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B):

    Time: up to 162 days following dose administration

    Description: Fold increase in functional antibody titers 7±1 days and 21±2 days after primary immunization and at 21±2 days, 28±4 days, 63±5 days, and 162±7 days after the boost immunization.

    Measure: For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B):

    Time: up to 162 days following dose administration

    Description: Number of subjects with seroconversion defined as a minimum of 4-fold increase of functional antibody titers as compared to baseline at 7±1 days and 21±2 days after primary immunization and at 21±2 days, 28±4 days, 63±5 days, and 162±7 days after the boost immunization.

    Measure: For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B):

    Time: up to 162 days following dose administration

    Description: Functional antibody responses at 7±1 days, 21±2 days, 29±3 days, 42±3 days, 84±5 days, and 183±7 days after the primary immunization.

    Measure: For BNT162c2 (SD):

    Time: up to 183 days following dose administration

    Description: Fold increase in functional antibody titers at 7±1 days, 21±2 days, 29±3 days, 42±3 days, 84±5 days, and 183±7 days after the primary immunization.

    Measure: For BNT162c2 (SD):

    Time: up to 183 days following dose administration

    Description: Number of subjects with seroconversion defined as a minimum of 4-fold increase of functional antibody titers as compared to baseline at 7±1 days, 21±2 days, 29±3 days, 42±3 days, 84±5 days, and 183±7 days after the primary immunization.

    Measure: For BNT162c2 (SD):

    Time: up to 183 days following dose administration
    18 Hypertonic Saline Nasal Irrigation and Gargling for Suspected or Confirmed COVID-19: Pragmatic Web-based Bayesian Adaptive Randomised Controlled Trial (ELVIS COVID-19)

    ELVIS COVID-19 is a pragmatic web-based Bayesian adaptive randomised controlled, parallel group trial of hypertonic saline nasal irrigation and gargling (HSNIG) compared to standard care in participants with clinically suspected or confirmed COVID-19 being managed at home.

    NCT04382131
    Conditions
    1. Upper Respiratory Tract Infections
    2. Virus
    3. COVID
    4. Virus Shedding
    5. Virus Diseases
    Interventions
    1. Other: NaCl Solution
    MeSH:Respiratory Tract Infections Virus Diseases
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: Time until participant reports well

    Measure: Time to resolution of symptoms as defined by the single question 'how unwell do you feel today'.

    Time: Maximum of 14 days

    Secondary Outcomes

    Description: Recorded using validated Wisconsin Upper Respiratory Symptom Survey-24 (WURSS-24) questionnaire and daily diaries. The WURSS-24 questionnaire assesses the interference on daily life and severity of symptoms on a scale of 1 (not at all) to 7 (severe)

    Measure: Severity of all symptoms

    Time: 1-14 days or until the participant reports that they are well

    Description: Recorded using validated Wisconsin Upper Respiratory Symptom Survey-24 (WURSS-24) questionnaire and daily diaries. The WURSS-24 questionnaire assesses the interference on daily life and severity of symptoms on a scale of 1 (not at all) to 7 (severe)

    Measure: The length of time for individual symptoms to resolve

    Time: 1-14 days or until the participant reports that they are well

    Description: Recorded using validated Wisconsin Upper Respiratory Symptom Survey-24 (WURSS-24) questionnaire and daily diaries. The WURSS-24 questionnaire assesses the interference on daily life and severity of symptoms on a scale of 1 (not at all) to 7 (severe)

    Measure: Severity of individual symptoms

    Time: 1-14 days or until the participant reports that they are well

    Description: Number of participants and frequency of contacts

    Measure: Contacting healthcare (NHS 24, OOH, GP)

    Time: 1-14 days or until the participant reports that they are well

    Description: Number of participants and frequency of contacts

    Measure: Participants needing GP appointments

    Time: 1-14 days or until the participant reports that they are well

    Description: Number of participants

    Measure: Participants attending hospital

    Time: 1-14 days or until the participant reports that they are well

    Description: Number of days

    Measure: Length of stay in hospital if admitted

    Time: 1-14 days or until the participant reports that they are well

    Description: Number of participants

    Measure: Number of participants reporting over the counter medication use

    Time: 1-14 days or until the participant reports that they are well

    Description: Number of people within participant's household who develop symptoms

    Measure: Reduction in transmission to household contacts

    Time: 1-14 days or until the participant reports that they are well

    Description: Number of participants in intervention arm reporting side effects

    Measure: Number of participants reporting side effects of nasal irrigation

    Time: 1-14 days or until the participant reports that they are well

    Description: Participants asked if they have experienced common side effects or other and to rate the severity on a 7 point scale of 'Did not have this side effect' to 'severe'

    Measure: Types and severity of side effects reported

    Time: 1-14 days or until the participant reports that they are well

    Description: Estimated cost requested when participant states over the counter medication used

    Measure: Cost of over the counter medication used

    Time: 1-14 days or until the participant reports that they are well
    19 The Efficacy of Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial

    The use of both levamisole & Isoprinosine has both synergistic and complementary effect in the treatment of COVID 19 infection

    NCT04383717
    Conditions
    1. Respiratory Tract Infections
    Interventions
    1. Drug: Levamisole and isoprinosine
    2. Drug: Azithromycin and hydroxychloroquine
    MeSH:Respiratory Tract Infections
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: Improvement of fever in degrees celsius

    Measure: COVID 19 induced fever in both groups

    Time: 4 weeks

    Description: improvement of dyspnea by normalization of respiratory rate

    Measure: COVID 19 induced dyspnea in both groups

    Time: 4 weeks

    Description: PCR of COVID 19 changes from positive to negative

    Measure: COVID 19 viral load in both groups

    Time: 4 weeks

    Secondary Outcomes

    Description: CRP in mg/dL

    Measure: laboratory clearance in both groups: CRP in mg/dL

    Time: 4 weeks
    20 A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune System

    The aim of this study is to investigate whether vaccination of healthcare professionals with VPM1002 could reduce the number of days absent from work due to respiratory disease (with or without documented SARS-CoV-2 infection). VPM1002 is a vaccine that is a further development of the old Bacillus Calmette-Guérin (BCG) vaccine, which has been used successfully as a vaccine against tuberculosis for about 100 years, especially in developing countries. VPM1002 has been shown in various clinical studies to be significantly safer than the BCG vaccine. VPM1002 strengthens the body's immune defence and vaccination with BCG reduces the frequency of respiratory diseases. It is therefore assumed that a VPM1002 vaccination could also provide (partial) protection against COVID-19 disease caused by the new corona virus "SARS-CoV 2". A total of 1200 health care professionals (doctors, nurses and paramedical staff) with high expected exposure to SARSCoV-2 infected patients will receive a single dose of either VPM1002 or Placebo. All subjects will be requested to enter data regarding absenteeism, adverse events / serious adverse events, hospitalizations, intensive care unit admissions into an online questionnaire.

    NCT04387409
    Conditions
    1. Infection, Respiratory Tract
    Interventions
    1. Biological: VPM1002
    2. Biological: Placebo
    MeSH:Respiratory Tract Infections
    HPO:Respiratory tract infection

    Primary Outcomes

    Measure: Number of days absent from work due to respiratory disease (with or without documented SARS-CoV-2 infection)

    Time: From day 0 to day 240

    Secondary Outcomes

    Measure: Cumulative incidence of documented SARS-CoV-2 infection

    Time: From day 0 to day 240

    Measure: Number of days absent from work due to documented SARS-CoV-2 infection

    Time: From day 0 to day 240

    Measure: Number of days absent from work due to exposure to person with documented SARS-CoV-2 infection

    Time: From day 0 to day 240

    Measure: Number of days absent from work due to symptoms of respiratory disease, documented SARS-CoV-2 infection, or fever (≥ 38 °C)

    Time: From day 0 to day 240

    Measure: Number of days of self-reported fever (≥ 38 °C)

    Time: From day 0 to day 240

    Measure: Number of days of self-reported acute respiratory symptoms

    Time: From day 0 to day 240

    Measure: Cumulative incidence of self-reported acute respiratory symptoms

    Time: From day 0 to day 240

    Measure: Cumulative incidence of death for any reason

    Time: From day 0 to day 240

    Measure: Cumulative incidence of death due to documented SARS-CoV-2 infection

    Time: From day 0 to day 240

    Measure: Cumulative incidence of ICU admission for any reason

    Time: From day 0 to day 240

    Measure: Cumulative incidence of ICU admission due to documented SARS-CoV-2 infection

    Time: From day 0 to day 240

    Measure: Cumulative incidence of hospital admission for any reason

    Time: From day 0 to day 240

    Measure: Cumulative incidence of hospital admission due to documented SARS-CoV-2 infection

    Time: From day 0 to day 240
    21 Hydroxychloroquine and Lopinavir/ Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms: "The Hope Coalition"

    The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in controlling this disease in hospitalized patients with moderate and / or severe cases of this disease. Hydroxychloroquine and lopinavir / ritonavir have been shown to inhibit SARS-CoV viral replication in experimental severe acute respiratory symptoms models and have similar activity against SARS-CoV2. Although widely used in studies of critically ill patients, to date, no study has demonstrated its role on the treatment of high-risk, newly diagnosed patients with COVID-19 and mild symptoms.

    NCT04403100
    Conditions
    1. COVID-19
    2. Coronavirus Infection
    3. Virus Disease
    4. Acute Respiratory Infection
    5. SARS-CoV Infection
    Interventions
    1. Drug: Hydroxychloroquine Sulfate Tablets
    2. Drug: Lopinavir/ Ritonavir Oral Tablet
    3. Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets
    4. Drug: Placebo
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Coronavirus Infections Virus Diseases Severe Acute Respiratory Syndrome
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: Hospitalization is defined as at least 24 hours of acute care in a hospital or similar acute care facility (emergency settings, temporary emergency facilities created for acute care of COVID-19 pandemic)

    Measure: Proportion of participants who were hospitalized for progression of COVID-19 disease

    Time: Measuring during 28-day period since randomization (Intention to treat analysis)

    Measure: Proportion of participants who died due to COVID-19 progression and/ or complications

    Time: Measuring during 28-day period since randomization (Intention to treat analysis)

    Secondary Outcomes

    Description: Viral load change on 03, 07, 10 and 14 after randomization (200 patients per arm)

    Measure: Proportion of participants with viral load change on 03, 07, 10 and 14 after randomization

    Time: Measuring during 14-day period since randomization

    Description: Proportion of participants with clinical improvement, defined as normalization of temperature, Respiratory rate, SaO2, and cough relief (> 50% compared to baseline measured on a visual analog scale) in the last 72 hours.

    Measure: Time to clinical improvement

    Time: Measuring during 28-day period since randomization

    Description: Proportion of participants with clinical improvement, defined as as time to need for hospitalization due to dyspnea, death, need for mechanical ventilation, shock and need for vasoactive amines;

    Measure: Time to clinical failure

    Time: Measuring during 28-day period since randomization

    Description: Proportion of participants with hospitalization for any cause

    Measure: Hospitalization for any cause

    Time: Measuring during 28-day period since randomization

    Measure: Proportion of participants who died due to pulmonary complications

    Time: Measuring during 28-day period since randomization

    Measure: Proportion of participants who died due to cardiovascular complications

    Time: Measuring during 28-day period since randomization

    Description: Evaluation of adverse events evaluated as associated to any of study arms

    Measure: Proportion of participants who presented with adverse events

    Time: Measuring during 28-day period since randomization

    Description: Proportion of participants who presented sustained improvement on respiratory scale defined as at least 48 hours of improvement.

    Measure: Time to improvement on respiratory scale symptoms

    Time: Measuring during 28-day period since randomization

    Measure: proportion of non-adherent participants to any of study drugs

    Time: Measuring during 10-day period since randomization
    22 A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in the SARS-CoV-2 Pandemic by Modulating the Immune System

    The aim of this study is to investigate whether vaccination of elderly with VPM1002 could reduce hospital admissions and/or severe respiratory infectious diseases in the SARS-CoV-2 pandemic . VPM1002 is a vaccine that is a further development of the old Bacillus Calmette-Guérin (BCG) vaccine, which has been used successfully as a vaccine against tuberculosis for about 100 years, especially in developing countries. VPM1002 has been shown in various clinical studies to be significantly safer than the BCG vaccine. VPM1002 strengthens the body's immune defence and vaccination with BCG reduces the frequency of respiratory diseases. It is therefore assumed that a VPM1002 vaccination could also provide (partial) protection against COVID-19 disease caused by the "new corona virus" SARS-CoV 2.

    NCT04435379
    Conditions
    1. Infection, Respiratory Tract
    Interventions
    1. Biological: VPM1002
    2. Biological: Placebo
    MeSH:Communicable Diseases Infection Respiratory Tract Infections
    HPO:Respiratory tract infection

    Primary Outcomes

    Measure: Number of days with severe respiratory disease at hospital and/or at home

    Time: From day 0 to day 240

    Secondary Outcomes

    Measure: Cumulative incidence of hospital admissions

    Time: From day 0 to day 240

    Measure: Cumulative incidence of documented SARS-CoV-2 infection

    Time: From day 0 to day 240

    Measure: Number of days with self-reported fever (≥ 38 ºC)

    Time: From day 0 to day 240

    Measure: Number of days with self-reported acute respiratory symptoms

    Time: From day 0 to day 240

    Measure: Cumulative incidence of self-reported acute respiratory symptoms

    Time: From day 0 to day 240

    Measure: Cumulative incidence of death for any reason

    Time: From day 0 to day 240

    Measure: Cumulative incidence of death due to documented SARS-CoV-2 infection

    Time: From day 0 to day 240

    Measure: Cumulative incidence of ICU admission for any reason

    Time: From day 0 to day 240

    Measure: Cumulative incidence of ICU admission due to documented SARS-CoV-2 infection

    Time: From day 0 to day 240

    Measure: Cumulative incidence of hospital admission due to documented SARSCoV- 2 infection

    Time: From day 0 to day 240
    23 Randomized Controlled Phase 2/3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection

    This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.

    NCT04452565
    Conditions
    1. Coronavirus Infection
    2. Severe Acute Respiratory Infection
    3. Severe Acute Respiratory Syndrome Coronavirus 2
    Interventions
    1. Drug: Drug: NA-831
    2. Combination Product: NA-831 and Atazanavir
    3. Combination Product: NA-831and Dexamethasone
    4. Combination Product: Atazanavir and Dexamethasone
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: Time (hours) from randomization to recovery defined as 1) absence of fever, as defined as at least 48 hours since last temperature ≥ 38.0°C without the use of fever-reducing medications AND 2) absence of symptoms of greater than mild severity for 24 hours AND 3) not requiring supplemental oxygen beyond pre-COVID baseline AND 4) freedom from mechanical ventilation or death

    Measure: 1. Time (Hours) to recovery

    Time: [ Time Frame: 36 days ]

    Secondary Outcomes

    Description: Time to resolution of fever defined as at least 48 hours since last temperature ≥ 38.0°C without the use of fever-reducing medications

    Measure: Time fever resolution

    Time: [ Time Frame: 36 days ]
    24 Reducing Asymptomatic Infection With Vitamin D in Coronavirus Disease

    This study is intended to address whether oral daily vitamin D supplementation reduces infection with SARS-CoV-2 in healthy young adults. The primary aim of the study is to demonstrate a reduction in 'silent' seroconversion rates, consistent with asymptomatic transmission of SARS-CoV-2, in a young healthy adult population following 24 weeks of taking oral vitamin D supplemented at a dose of 1000 I.U. daily, versus matching placebo. The secondary aims of this study are to explore: 1. Any effect on symptomatic illness. 2. The background 'point' prevalence and subsequent rate of increase in seropositivity for SARS-CoV-2 in healthy young adults. 3. The individual reductions in seropositivity to SARS-CoV-2 over time, and changes in seropositivity in a defined young adult population over time. 4. Where salivary Immunoglobulin A (IgA) may be used to provide an alternative/ complementary serological method 5. The effect (if any) of vitamin D supplementation on seroconversion rates stratified by: i) level of baseline vitamin D 'deficiency/ insufficiency/ sufficiency' status; ii) extent of BMI-defined normal/overweight/obesity cut-offs and iii) gender.

    NCT04476680
    Conditions
    1. SARS-CoV Infection
    2. Vitamin D D
    3. Vitamin D Deficiency
    4. Covid19
    5. Acute Respiratory Tract Infection
    Interventions
    1. Dietary Supplement: Vitamin D 1000 IU
    2. Drug: Placebo
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome Vitamin D Deficiency Asymptomatic Infections
    HPO:Low levels of vitamin D Respiratory tract infection

    Primary Outcomes

    Description: asymptomatic seroconversion for SARS-CoV-2

    Measure: Seroconversion

    Time: 24 weeks

    Description: asymptomatic seroconversion for SARS-CoV-2

    Measure: Interim analysis - seropositivity at 12 weeks

    Time: 12 weeks

    Secondary Outcomes

    Description: Sensitivity and specificity of dried blood spot assay compared with venous blood serology

    Measure: Dried Blood Spot performance

    Time: 24 weeks

    Description: Sensitivity and specificity of salivary IgA compared with venous blood serology

    Measure: Salivary IgA performance

    Time: 24 weeks

    Description: The background 'point' prevalence and subsequent rate of increase in seropositivity for SARS-CoV-2 in healthy young adults.

    Measure: Prevalence of SARS-CoV-2

    Time: 24 weeks

    Description: The individual reductions in seropositivity to SARS-CoV-2 over time, and changes in seropositivity in a defined young adult population over time

    Measure: Change in seropositivity

    Time: 24 weeks

    Description: The effect of vitamin D supplementation on seroconversion rates stratified by: i) level of baseline vitamin D 'deficiency/ insufficiency/ sufficiency' status; ii) extent of BMI-defined normal/overweight/obesity cut-offs, iii) gender iv) ethnicity

    Measure: Change in seroconversion rate

    Time: 24 weeks
    25 Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19

    The overall objective of the study is to determine the therapeutic effect and tolerance of Tocilizumab combined with Dexamethasone in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19). Tocilizumab (TCZ) is an anti-human IL-6 receptor monoclonal antibody that inhibits signal transduction by binding sIL-6R and mIL-6R. The study has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur prior to offering Dexamethasone alone or Dexamethasone +Tocilizumab administration to patients enrolled in the CORIMUNO-19 cohort. Tocilizumab will be administered to consenting adult patients hospitalized with COVID-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation or critical pneumonia requiring mechanical ventilation. Patients who will chose not to receive Tocilizumab will receive standard of cares. Outcomes of Tocilizumab-treated patients will be compared with outcomes of standard of care (including Dexamethasone) treated patients

    NCT04476979
    Conditions
    1. Coronavirus Infection
    2. SARS (Severe Acute Respiratory Syndrome)
    3. Virus Diseases
    4. Coronaviridae Infections
    5. Nidovirales Infections
    6. RNA Virus Infections
    7. Respiratory Tract Infections
    8. Respiratory Tract Disease
    Interventions
    1. Drug: Tocilizumab
    2. Drug: Dexamethasone
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Virus Diseases Coronavirus Infections Severe Acute Respiratory Syndrome RNA Virus Infections Coronaviridae Infections Nidovirales Infections Respiratory Tract Diseases
    HPO:Respiratory tract infection

    Primary Outcomes

    Description: Survival without needs of ventilator utilization (including non invasive ventilation and high flow) at day 14. Thus, events considered are needing ventilator utilization (including Non Invasive Ventilation, NIV or high flow), or death.

    Measure: Survival without needs of ventilator utilization at day 14

    Time: day 14

    Secondary Outcomes

    Description: WHO progression scale: Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2>=150 OR SpO2/FIO2>=200: 7 Mechanical ventilation, (pO2/FIO2<150 OR SpO2/FIO2<200) OR vasopressors (norepinephrine >0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2<150 AND vasopressors (norepinephrine >0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10

    Measure: WHO progression scale at day 7 and 14

    Time: day 7 and day 14

    Description: Overall survival

    Measure: Overall survival at 14, 28, 60 and 90 days

    Time: 14, 28, 60 and 90 days

    Description: Cumulative incidence of discharge alive

    Measure: Cumulative incidence of discharge alive at 14 and 28 days

    Time: 14 and 28 days

    Description: Survival without needs of mechanical ventilation at day 1. New DNR order (if given after the inclusion of the patient) will be considered as an event at the date of the DNR.

    Measure: Survival without needs of mechanical ventilation at day 1

    Time: day 1

    Description: Cumulative incidence of oxygen supply independency

    Measure: Cumulative incidence of oxygen supply independency at 14 and 28 days

    Time: 14 and 28 days
    26 A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers

    The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in combination with NA-831 in 48 healthy volunteers.

    NCT04480333
    Conditions
    1. Covid19
    2. Corona Virus Infection
    3. Severe Acute Respiratory Syndrome
    4. Severe Acute Respiratory Infection
    5. Severe Acute Respiratory Syndrome (SARS) Pneumonia
    6. Severe Acute Respiratory Syndrome of Upper Respiratory Tract
    7. Neurodegeneration
    8. Neuroinflammatory Response
    Interventions
    1. Drug: Drug: NA-831 - 0.10 mg/kg
    2. Drug: Placebo- 0.10 mg/kg
    3. Drug: Drug: NA-831 - 0.20 mg/kg
    4. Drug: Placebo- 0.20 mg/kg
    5. Drug: Drug: GS-5734 - 1.00 mg/kg
    6. Drug: Placebo- 1.00 mg/kg
    7. Drug: Drug: GS-5734 - 2.00 mg/kg
    8. Drug: Placebo- 2.00 mg/kg
    9. Combination Product: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)
    10. Combination Product: Placebo 0.10 mg + 1.00 mg/kg
    11. Combination Product: Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)
    12. Combination Product: Placebo 0.20 mg + 2.00 mg/kg
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Virus Diseases Severe Acute Respiratory Syndrome Coronavirus Infections Pneumonia Syndrome Nerve Degeneration
    HPO:Neurodegeneration Pneumonia Respiratory tract infection

    Primary Outcomes

    Description: AEs will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0

    Measure: Proportion of Participants Experiencing any Treatment-Emergent Adverse Events

    Time: First dose date up to Day 30 Follow-up Assessment

    Description: This will be assessed at various time points by clinical laboratory tests and vital signs.

    Measure: Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities

    Time: First dose date up to Day 30 Follow-up Assessment

    Secondary Outcomes

    Description: Monitoring of the levels of drugs in subject sera at various time points to elucidate the maximum concentration (Cmax) of NA-831 and GS-5734 in human serum.

    Measure: Maximum Concentration (Cmax) - Pharmacokinetic Assessment

    Time: 7 days

    Description: Monitoring of the levels of drugs in subject sera at various time points to elucidate the time to maximum concentration (Tmax) of NA-831 and GS-5734 in human serum

    Measure: Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment

    Time: 7 days

    Description: Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve from time of administration to the last measurable of NA-831 and GS-5734

    Measure: AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment

    Time: 7 days

    Description: Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve extrapolated to infinity (AUC0-∞) of NA-831 and GS-5734

    Measure: Area Under the Curve Extrapolated to Infinity (AUC0-∞)

    Time: 7 days

    Description: Monitoring of the levels of drugs in subject sera at various time points to elucidate the half-life (t1/2) of NA-831 and GS-5734 in human serum.

    Measure: Half-Life (t1/2) - Pharmacokinetic Assessment

    Time: 7 days

    Description: Monitoring of the levels of drugs in subject sera through various time points to elucidate the volume of distribution (Vd) of NA-831 and GS-5734 in human serum.

    Measure: Volume of Distribution (Vd) - Pharmacokinetic Assessment

    Time: 7 days

    Description: Monitoring of the levels of drugs in subject sera through at various time points to elucidate clearance [CL] of NA-831 and GS-5734 in human serum.

    Measure: Clearance [CL] - Pharmacokinetic Assessment

    Time: 7 days
    27 A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults in the Era of Coronavirus Disease 2019 (MITIGATE)

    MITIGATE is a prospective, open-label, parallel-group, randomized, pragmatic clinical trial. The MITIGATE Study has been designed to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), also known as Vascepa®, compared to usual standard of care to prevent and reduce the sequelae of laboratory-confirmed viral upper respiratory infection (URI)-related (i.e., COVID-19, influenza, and other known viral respiratory pathogens) morbidity and mortality in a high-risk cohort of adults with established atherosclerotic cardiovascular disease (ASCVD).

    NCT04505098
    Conditions
    1. Covid19
    2. Atherosclerosis
    3. Cardiovascular Diseases
    4. Upper Respiratory Tract Infections
    Interventions
    1. Drug: Icosapent ethyl
    MeSH:Respiratory Tract Infections Cardiovascular Diseases Atherosclerosis
    HPO:Abnormality of the cardiovascular system Atherosclerosis Respiratory tract infection Type IV atherosclerotic lesion

    Primary Outcomes

    Description: Confirmed viral URIs (i.e., including recurrent events) (i.e., COVID-19, influenza, and other known viral respiratory pathogens) based on laboratory testing (i.e., FDA or locally-approved testing modalities) with an oxygen saturation <94% on room air and/or requiring any form of supplemental oxygen.

    Measure: Percentage of patients with moderate or severe confirmed viral URIs

    Time: 0-12 months

    Description: At any point in time based on a 7-point ordinal scale (i.e., 1 = death, 2 = mechanically ventilated/extracorporeal membrane oxygenation, 3 = high flow supplemental oxygen, 4 = low flow supplemental oxygen, 5 = hospitalized with no supplemental oxygen requirements, 6 = urgent care or emergency department visit not leading to hospitalization, and 7 = no relevant clinical encounters)

    Measure: Worst clinical status due to a confirmed viral URI

    Time: 0-12 months

    Other Outcomes

    Measure: Percentage of participants who die due to any cause

    Time: 0-12 months

    Description: Death due to any cause, hospitalization for myocardial infarction, or hospitalization for ischemic stroke

    Measure: Percentage of participants experiencing a major adverse cardiovascular event

    Time: 0-12 months

    Description: Major adverse cardiovascular events, hospitalization for acute coronary syndrome, and coronary revascularization (i.e., percutaneous coronary intervention and/or coronary artery bypass graft)

    Measure: Percentage of participants experiencing an expanded major adverse cardiovascular event

    Time: 0-12 months

    Measure: Percentage of participants who are hospitalized for heart failure

    Time: 0-12 months

    Measure: Percentage of participants who are hospitalized for any reason

    Time: 0-12 months

    Measure: Percentage of participants who have an emergency department visit for any reason

    Time: 0-12 months

    HPO Nodes


    HP:0011947: Respiratory tract infection
    Genes 664
    CCDC39 KMT2D RSPH1 DOCK8 NKX2-1 CCNO SPAG1 LIMK1 MPLKIP RAG1 DSG1 BIRC3 ELP1 TSC2 IL17F BLNK BACH2 SGSH IKBKB CD79A AFF4 ARID1B TNFRSF13C CD19 DNAH1 MYO5A AICDA NOTCH3 ELN LAMTOR2 NADK2 CTLA4 DPM2 PWAR1 GATA6 SFTPC FOXN1 MESP2 ELANE CD81 PNP MED25 ZAP70 RAG2 WRAP53 DNAAF1 STAT3 ATM LTBP3 CLCA4 DNAH9 BTK RSPH3 TERT TYK2 LRBA RSPH4A SOX11 RYR1 TNNT2 SMARCD2 GAS8 SLC5A7 KIF1A ROR2 NCF4 COLQ TNFRSF13B HLA-B CCDC65 COL11A2 ORC6 DCLRE1C CTLA4 CACNA1C GBA RNF113A ICOS SETBP1 CYBC1 MGP VPS33A COL13A1 MYSM1 DNAAF4 FLI1 MECP2 MAN2B1 HLA-DQA1 SCNN1A GLB1 IL21R CSF2RB SELENON INPPL1 CD3G ACADVL COL6A3 NSMCE3 AGA CCDC65 HGSNAT AP3D1 NFIX EXOSC9 RAG2 KIAA0586 FCGR2A ABCA12 NFKB2 TFRC NDN MAPK1 LAMA2 NCF4 ARSB LYST RAG1 TPP2 TGFB1 INPPL1 RAG2 TNFSF11 XIAP UNG SCNN1A DNAAF6 SCN10A IL2RG CCDC103 CLCN7 IGHM GNPTAB DNAAF4 CXCR4 PLEC HLA-DPB1 OCRL RFXAP SCN11A CFB TNNI3 TINF2 DCLRE1C MAGEL2 TAF1 SCNN1B CARD11 USB1 GTF2IRD1 CCDC103 SNORD115-1 IL2RG HLA-DQB1 TBC1D23 DLL3 RFXANK MYO9A SCNN1G CD79A ICOS RFC2 TAP1 CD3D FOXJ1 AGRN PIK3R1 WIPF1 RSPH4A IL2RG ACTA1 SRP54 RPGR SNAP25 TSC1 CORO1A IRF8 NCF2 GAS8 ZNHIT3 FOXP1 EP300 JAGN1 ZBTB24 TGFB1 TNFRSF13B CD3E DNAL1 EXTL3 NCF1 SNRPN B2M CLIP2 SCNN1G SFTPC LRRC56 WAS RMRP FUCA1 RSPH9 PEX13 GATA4 CFI ERCC3 FOXP1 ITGA3 PCGF2 TNFRSF13C ATP6V0A2 DNMT3B LEP BCR ZBTB24 NELFA RNF125 NECTIN1 EPM2A TGM1 CCDC40 JAK3 NEK10 MYPN RAC1 CREBBP DNAI2 PLG DDR2 UGP2 NME8 COL6A1 SLC25A1 ECM1 CD3E NFKBIA IGLL1 CHRM3 PRTN3 COG6 CD8A STX1A DNAI1 CYBB IDUA GSN EPG5 TCIRG1 DNAJB13 EDARADD TERT CR2 SOX4 NSD2 GAA TARS1 LEPR ELP1 ALMS1 IL2RB SULT2B1 RAG2 SLC25A24 SMPD1 WDR19 CHAMP1 DNAJB13 FOXP3 RNU4ATAC PLP1 ARID1A CFAP410 BTK TCTN3 RFXANK MYH3 FCN3 SMARCE1 ALPL SLC18A3 IL17RA NR2F2 NKX2-1 SCNN1G CCBE1 SLC52A3 PWRN1 DCLRE1C RYR1 AGA CIITA CR2 LRRC6 PIGN CFAP298 DNAAF5 CCNO BLM CFTR NCF1 CR2 IL2RA LCK UMPS USP9X CD3D ARID2 RUNX2 SLC35C1 TIMM8A NGLY1 NFKB2 CCDC114 TPM3 SCNN1B ADA LRRC56 PEPD IPW KATNIP LYST GRHL3 CCDC151 NBN SYT2 SPAG1 PRKCD LAMB2 CTC1 PMM2 DNAAF3 FLNC DNAAF1 POLR3A LIPN STAT1 TECPR2 SCNN1B RAG1 SDR9C7 ASAH1 DNAAF6 CRELD1 MYSM1 OSTM1 GBA CYBA RNU4ATAC COL13A1 VAMP1 MGP SMARCC2 MCIDAS G6PC3 IL17RC PSAP KAT6B PIK3R1 CD81 SLC1A4 NOP10 NGLY1 MANBA SHROOM4 ALB SMARCD1 SCNN1A CD19 ALMS1 GUSB TTC25 SMN1 RIPK1 UNC119 IGHM CD79B CFAP221 SAMD9 CYP4F22 GTF2H5 GLI3 IGLL1 SLC29A3 RPGR SCNN1B STK36 PLOD1 DNAAF5 GMNN RAG1 GNS COL11A2 OFD1 TNFRSF11A MALT1 NFE2L2 CD19 DCTN4 COG4 SCNN1A CD40LG NME8 SELENON ADNP CFTR NPAP1 CFTR DOCK8 CFAP298 SMPD1 RAG1 P4HTM MAN2B1 SLC26A2 CFAP300 RAB3GAP2 ALG12 JAK3 GTF2E2 IL21 BCL10 NRAS PRKDC TNFRSF13C SH3KBP1 ZNF341 NXN RSPH9 RFXAP SPEF2 MSN LIG4 MCM4 TBCE GALNS SLC12A6 NIPBL STAT3 ZMYND10 IL7R NAGLU HELLS CTSC NIPAL4 RASGRP1 SMARCB1 SP110 LETM1 RSPH1 CCDC39 ARMC4 LAMTOR2 TNFRSF1A IKZF1 IKBKB DNAI2 MBTPS2 FBLN5 ACP5 PTPRC NFKB2 ZAP70 TPM2 TCIRG1 NEK10 ARMC4 MS4A1 MTHFD1 CARMIL2 UBE2A EGFR RYR1 ADA DNAI1 PLCG2 PTPN22 DNMT3B BAZ1B TAPBP RTEL1 ABCA12 SNX10 CSF2RA MESP2 SMARCA4 AK2 DNAH11 KCNJ6 HACD1 DCLRE1C SAMD9L PNP ITGA7 ALOXE3 HLA-DPA1 HERC2 SLC46A1 LRRC8A IER3IP1 TSC2 TGFB1 TRAF3IP2 HPS6 ADA ICOS FLNA TRIP4 FMO3 DPF2 GFI1 ARID1B IRAK4 MKRN3-AS1 VPS33A DNAAF2 NOTCH2 SFTPA2 PCNT CRLF1 ELANE DNAH5 NFKB1 PANK2 GBA GAS2L2 GTF2I CD247 STAT1 RAG2 CCDC151 WAS EPG5 SLC25A22 DYNC2I2 XIAP SLC35A1 GNPTAB TK2 MS4A1 IFNGR1 LEPR CRKL CIITA NPM1 ZMYND10 COL6A2 ATM RNF168 GAS2L2 CDCA7 PRPS1 EHMT1 ERF NHLRC1 TBX6 MUC5B VPS13A RFX5 ASAH1 DNAH5 HYDIN FCGR3A RELB ADAMTS3 SCN9A TTC12 SH2D1A PTPN22 LEP CYBA PGM3 IL17RA MKRN3 NOS1 AFF4 ERCC2 SDCCAG8 IFIH1 CD79B TBC1D24 CHD7 GATA2 POLE LRRC6 TERC TNFRSF13B TAP2 CFTR OFD1 WASHC5 RANBP2 IL7R MYL2 TRAIP CCDC22 IGH CCDC40 IL2RG SNORD116-1 ALOX12B NFKB1 STING1 NCF2 TRPS1 SGCG PARN CHAT TSC1 TBL2 CTCF ACTA1 CACNA1B UBB PIK3CD PEPD DNAAF3 TTC25 CARD11 DNAAF2 CXCR4 MASP2 IL6ST TBC1D24 DRC1 TBCD TCF3 CYBB PIK3R1 SMN1 RSPH3 COG4 TNFSF12 CSPP1 KIF20A USP9X NHP2 HYDIN NBN PYROXD1 CASP8 IL7R SCNN1G CCDC114 TNFSF12 BTK SPINK5 BLNK CD55 IDUA USB1 SIK1 FLNA CLEC7A MAP3K20 KPTN RFX5 FAT4 DKC1 KDM6A IDUA POLA1 TRIP11 PGM3 GUSB DNAH11 KRAS
    Protein Mutations 1
    H275Y
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0011947: Respiratory tract infection
    Genes 664
    CCDC39 KMT2D RSPH1 DOCK8 NKX2-1 CCNO SPAG1 LIMK1 MPLKIP RAG1 DSG1 BIRC3 ELP1 TSC2 IL17F BLNK BACH2 SGSH IKBKB CD79A AFF4 ARID1B TNFRSF13C CD19 DNAH1 MYO5A AICDA NOTCH3 ELN LAMTOR2 NADK2 CTLA4 DPM2 PWAR1 GATA6 SFTPC FOXN1 MESP2 ELANE CD81 PNP MED25 ZAP70 RAG2 WRAP53 DNAAF1 STAT3 ATM LTBP3 CLCA4 DNAH9 BTK RSPH3 TERT TYK2 LRBA RSPH4A SOX11 RYR1 TNNT2 SMARCD2 GAS8 SLC5A7 KIF1A ROR2 NCF4 COLQ TNFRSF13B HLA-B CCDC65 COL11A2 ORC6 DCLRE1C CTLA4 CACNA1C GBA RNF113A ICOS SETBP1 CYBC1 MGP VPS33A COL13A1 MYSM1 DNAAF4 FLI1 MECP2 MAN2B1 HLA-DQA1 SCNN1A GLB1 IL21R CSF2RB SELENON INPPL1 CD3G ACADVL COL6A3 NSMCE3 AGA CCDC65 HGSNAT AP3D1 NFIX EXOSC9 RAG2 KIAA0586 FCGR2A ABCA12 NFKB2 TFRC NDN MAPK1 LAMA2 NCF4 ARSB LYST RAG1 TPP2 TGFB1 INPPL1 RAG2 TNFSF11 XIAP UNG SCNN1A DNAAF6 SCN10A IL2RG CCDC103 CLCN7 IGHM GNPTAB DNAAF4 CXCR4 PLEC HLA-DPB1 OCRL RFXAP SCN11A CFB TNNI3 TINF2 DCLRE1C MAGEL2 TAF1 SCNN1B CARD11 USB1 GTF2IRD1 CCDC103 SNORD115-1 IL2RG HLA-DQB1 TBC1D23 DLL3 RFXANK MYO9A SCNN1G CD79A ICOS RFC2 TAP1 CD3D FOXJ1 AGRN PIK3R1 WIPF1 RSPH4A IL2RG ACTA1 SRP54 RPGR SNAP25 TSC1 CORO1A IRF8 NCF2 GAS8 ZNHIT3 FOXP1 EP300 JAGN1 ZBTB24 TGFB1 TNFRSF13B CD3E DNAL1 EXTL3 NCF1 SNRPN B2M CLIP2 SCNN1G SFTPC LRRC56 WAS RMRP FUCA1 RSPH9 PEX13 GATA4 CFI ERCC3 FOXP1 ITGA3 PCGF2 TNFRSF13C ATP6V0A2 DNMT3B LEP BCR ZBTB24 NELFA RNF125 NECTIN1 EPM2A TGM1 CCDC40 JAK3 NEK10 MYPN RAC1 CREBBP DNAI2 PLG DDR2 UGP2 NME8 COL6A1 SLC25A1 ECM1 CD3E NFKBIA IGLL1 CHRM3 PRTN3 COG6 CD8A STX1A DNAI1 CYBB IDUA GSN EPG5 TCIRG1 DNAJB13 EDARADD TERT CR2 SOX4 NSD2 GAA TARS1 LEPR ELP1 ALMS1 IL2RB SULT2B1 RAG2 SLC25A24 SMPD1 WDR19 CHAMP1 DNAJB13 FOXP3 RNU4ATAC PLP1 ARID1A CFAP410 BTK TCTN3 RFXANK MYH3 FCN3 SMARCE1 ALPL SLC18A3 IL17RA NR2F2 NKX2-1 SCNN1G CCBE1 SLC52A3 PWRN1 DCLRE1C RYR1 AGA CIITA CR2 LRRC6 PIGN CFAP298 DNAAF5 CCNO BLM CFTR NCF1 CR2 IL2RA LCK UMPS USP9X CD3D ARID2 RUNX2 SLC35C1 TIMM8A NGLY1 NFKB2 CCDC114 TPM3 SCNN1B ADA LRRC56 PEPD IPW KATNIP LYST GRHL3 CCDC151 NBN SYT2 SPAG1 PRKCD LAMB2 CTC1 PMM2 DNAAF3 FLNC DNAAF1 POLR3A LIPN STAT1 TECPR2 SCNN1B RAG1 SDR9C7 ASAH1 DNAAF6 CRELD1 MYSM1 OSTM1 GBA CYBA RNU4ATAC COL13A1 VAMP1 MGP SMARCC2 MCIDAS G6PC3 IL17RC PSAP KAT6B PIK3R1 CD81 SLC1A4 NOP10 NGLY1 MANBA SHROOM4 ALB SMARCD1 SCNN1A CD19 ALMS1 GUSB TTC25 SMN1 RIPK1 UNC119 IGHM CD79B CFAP221 SAMD9 CYP4F22 GTF2H5 GLI3 IGLL1 SLC29A3 RPGR SCNN1B STK36 PLOD1 DNAAF5 GMNN RAG1 GNS COL11A2 OFD1 TNFRSF11A MALT1 NFE2L2 CD19 DCTN4 COG4 SCNN1A CD40LG NME8 SELENON ADNP CFTR NPAP1 CFTR DOCK8 CFAP298 SMPD1 RAG1 P4HTM MAN2B1 SLC26A2 CFAP300 RAB3GAP2 ALG12 JAK3 GTF2E2 IL21 BCL10 NRAS PRKDC TNFRSF13C SH3KBP1 ZNF341 NXN RSPH9 RFXAP SPEF2 MSN LIG4 MCM4 TBCE GALNS SLC12A6 NIPBL STAT3 ZMYND10 IL7R NAGLU HELLS CTSC NIPAL4 RASGRP1 SMARCB1 SP110 LETM1 RSPH1 CCDC39 ARMC4 LAMTOR2 TNFRSF1A IKZF1 IKBKB DNAI2 MBTPS2 FBLN5 ACP5 PTPRC NFKB2 ZAP70 TPM2 TCIRG1 NEK10 ARMC4 MS4A1 MTHFD1 CARMIL2 UBE2A EGFR RYR1 ADA DNAI1 PLCG2 PTPN22 DNMT3B BAZ1B TAPBP RTEL1 ABCA12 SNX10 CSF2RA MESP2 SMARCA4 AK2 DNAH11 KCNJ6 HACD1 DCLRE1C SAMD9L PNP ITGA7 ALOXE3 HLA-DPA1 HERC2 SLC46A1 LRRC8A IER3IP1 TSC2 TGFB1 TRAF3IP2 HPS6 ADA ICOS FLNA TRIP4 FMO3 DPF2 GFI1 ARID1B IRAK4 MKRN3-AS1 VPS33A DNAAF2 NOTCH2 SFTPA2 PCNT CRLF1 ELANE DNAH5 NFKB1 PANK2 GBA GAS2L2 GTF2I CD247 STAT1 RAG2 CCDC151 WAS EPG5 SLC25A22 DYNC2I2 XIAP SLC35A1 GNPTAB TK2 MS4A1 IFNGR1 LEPR CRKL CIITA NPM1 ZMYND10 COL6A2 ATM RNF168 GAS2L2 CDCA7 PRPS1 EHMT1 ERF NHLRC1 TBX6 MUC5B VPS13A RFX5 ASAH1 DNAH5 HYDIN FCGR3A RELB ADAMTS3 SCN9A TTC12 SH2D1A PTPN22 LEP CYBA PGM3 IL17RA MKRN3 NOS1 AFF4 ERCC2 SDCCAG8 IFIH1 CD79B TBC1D24 CHD7 GATA2 POLE LRRC6 TERC TNFRSF13B TAP2 CFTR OFD1 WASHC5 RANBP2 IL7R MYL2 TRAIP CCDC22 IGH CCDC40 IL2RG SNORD116-1 ALOX12B NFKB1 STING1 NCF2 TRPS1 SGCG PARN CHAT TSC1 TBL2 CTCF ACTA1 CACNA1B UBB PIK3CD PEPD DNAAF3 TTC25 CARD11 DNAAF2 CXCR4 MASP2 IL6ST TBC1D24 DRC1 TBCD TCF3 CYBB PIK3R1 SMN1 RSPH3 COG4 TNFSF12 CSPP1 KIF20A USP9X NHP2 HYDIN NBN PYROXD1 CASP8 IL7R SCNN1G CCDC114 TNFSF12 BTK SPINK5 BLNK CD55 IDUA USB1 SIK1 FLNA CLEC7A MAP3K20 KPTN RFX5 FAT4 DKC1 KDM6A IDUA POLA1 TRIP11 PGM3 GUSB DNAH11 KRAS
    Protein Mutations 1
    H275Y
    SNP 0

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook